

# Laura Hondebrink

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2309564/laura-hondebrink-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

592  
citations

14  
h-index

24  
g-index

40  
ext. papers

724  
ext. citations

5.3  
avg, IF

4.25  
L-index

#	Paper	IF	Citations
32	Significant toxicity following an increase in poisonings with designer benzodiazepines in the Netherlands between 2010 and 2020.. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 231, 109244	4.9	0
31	Combining ecstasy and ethanol: higher risk for toxicity? A review. <i>Critical Reviews in Toxicology</i> , <b>2021</b> , 51, 1-14	5.7	3
30	Hyperthermia exacerbates the acute effects of psychoactive substances on neuronal activity measured using microelectrode arrays (MEAs) in rat primary cortical cultures in vitro. <i>Toxicology and Applied Pharmacology</i> , <b>2020</b> , 397, 115015	4.6	1
29	The Clinical Toxicology of 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): The Severity of Poisoning After Exposure to Low to Moderate and High Doses. <i>Annals of Emergency Medicine</i> , <b>2020</b> , 76, 303-317	2.1	2
28	Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 9	5.1	5
27	Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 271-281	3.2	4
26	New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017. <i>Addiction</i> , <b>2020</b> , 115, 716-725	4.6	17
25	Synthetic Cathinones and Their Potential Interactions with Prescription Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 75-82	3.2	9
24	Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2019</b> , 136, 102-112	5.8	20
23	A quarter of admitted poisoned patients have a mild poisoning and require no treatment: An observational study. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 66, 41-47	3.9	2
22	Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios. <i>NeuroToxicology</i> , <b>2019</b> , 74, 28-39	4.4	11
21	Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT). <i>Toxicology</i> , <b>2019</b> , 422, 69-75	4.4	3
20	Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA). <i>NeuroToxicology</i> , <b>2018</b> , 66, 87-97	4.4	25
19	Fatalities, Cerebral Hemorrhage, and Severe Cardiovascular Toxicity After Exposure to the New Psychoactive Substance 4-Fluoroamphetamine: A Prospective Cohort Study. <i>Annals of Emergency Medicine</i> , <b>2018</b> , 71, 294-305	2.1	21
18	Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 182, 193-224	13.9	51
17	Acute toxic effects related to 4-fluoroamphetamine. <i>Lancet, The</i> , <b>2017</b> , 389, 600	4.0	14
16	Neuropharmacological characterization of the new psychoactive substance methoxetamine. <i>Neuropharmacology</i> , <b>2017</b> , 123, 1-9	5.5	28

15	Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. <i>Toxicology in Vitro</i> , <b>2017</b> , 45, 60-71	3.6	36
14	Methylphenidate poisoning: relatively mild symptoms even after high-dose exposure. <i>Clinical Toxicology</i> , <b>2017</b> , 55, 941-942	2.9	1
13	Is the time right for in vitro neurotoxicity testing using human iPSC-derived neurons?. <i>ALTEX: Alternatives To Animal Experimentation</i> , <b>2016</b> , 33, 261-71	4.3	49
12	Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings. <i>NeuroToxicology</i> , <b>2016</b> , 55, 1-9	4.4	44
11	Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 157, 18-27	4.9	35
10	Structure-dependent inhibition of the human $\alpha 1$ GABAA receptor by piperazine derivatives: A novel mode of action. <i>NeuroToxicology</i> , <b>2015</b> , 51, 1-9	4.4	9
9	Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 147, 109-15	4.9	83
8	Methylphenidate intoxications in children and adults: exposure circumstances and evidence-based dose threshold for pre-hospital triage. <i>Clinical Toxicology</i> , <b>2015</b> , 53, 168-77	2.9	4
7	Additive inhibition of human $\alpha 1$ GABAA receptors by mixtures of commonly used drugs of abuse. <i>NeuroToxicology</i> , <b>2013</b> , 35, 23-9	4.4	13
6	Methamphetamine, amphetamine, MDMA (‘ecstasy’, MDA and mCPP modulate electrical and cholinergic input in PC12 cells. <i>NeuroToxicology</i> , <b>2012</b> , 33, 255-60	4.4	11
5	Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. <i>Critical Reviews in Toxicology</i> , <b>2012</b> , 42, 854-76	5.7	37
4	Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse. <i>NeuroToxicology</i> , <b>2011</b> , 32, 823-7	4.4	16
3	High concentrations of MDMA (‘ecstasy’) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. <i>Neuropharmacology</i> , <b>2011</b> , 61, 202-8	5.5	19
2	Are high-throughput measurements of intracellular calcium using plate-readers sufficiently accurate and reliable?. <i>Toxicology and Applied Pharmacology</i> , <b>2010</b> , 249, 247-8; author reply 249-50	4.6	5
1	Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. <i>Journal of Neurochemistry</i> , <b>2009</b> , 111, 624-33	6	12